- Home
- BCDA vs LMFA Comparison
BCDA vs LMFA Comparison
Compare BCDA & LMFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- LMFA
- Stock Information
- Founded
- BCDA N/A
- LMFA 2008
- Country
- BCDA United States
- LMFA United States
- Employees
- BCDA 17
- LMFA N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- LMFA Finance: Consumer Services
- Sector
- BCDA Health Care
- LMFA Finance
- Exchange
- BCDA Nasdaq
- LMFA Nasdaq
- Market Cap
- BCDA 13.7M
- LMFA 15.5M
- IPO Year
- BCDA N/A
- LMFA 2015
- Fundamental
- Price
- BCDA $1.32
- LMFA $1.08
- Analyst Decision
- BCDA Strong Buy
- LMFA Strong Buy
- Analyst Count
- BCDA 1
- LMFA 1
- Target Price
- BCDA $25.00
- LMFA $5.00
- AVG Volume (30 Days)
- BCDA 125.5K
- LMFA 1.8M
- Earning Date
- BCDA 11-12-2025
- LMFA 11-14-2025
- Dividend Yield
- BCDA N/A
- LMFA N/A
- EPS Growth
- BCDA N/A
- LMFA N/A
- EPS
- BCDA N/A
- LMFA N/A
- Revenue
- BCDA N/A
- LMFA $6,755,925.00
- Revenue This Year
- BCDA N/A
- LMFA N/A
- Revenue Next Year
- BCDA N/A
- LMFA $15.59
- P/E Ratio
- BCDA N/A
- LMFA N/A
- Revenue Growth
- BCDA N/A
- LMFA N/A
- 52 Week Low
- BCDA $1.00
- LMFA $0.89
- 52 Week High
- BCDA $3.20
- LMFA $5.14
- Technical
- Relative Strength Index (RSI)
- BCDA 43.26
- LMFA 47.43
- Support Level
- BCDA $1.25
- LMFA $1.06
- Resistance Level
- BCDA $1.45
- LMFA $1.27
- Average True Range (ATR)
- BCDA 0.08
- LMFA 0.12
- MACD
- BCDA 0.00
- LMFA 0.02
- Stochastic Oscillator
- BCDA 27.00
- LMFA 47.14
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About LMFA LM Funding America Inc.
LM Funding America Inc is a financial services company. The company provides funding to nonprofit community associations located in the state of Florida and to nonprofit community associations in the states of Washington and Colorado. Its products include Original Product and New Neighbor Guaranty. Its original product offering consists of providing funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It currently has two lines of business recently commenced cryptocurrency mining business and historical specialty finance business. The Company has two operating segments: Specialty Finance and Mining Operations, which generate the majority of its revenue.